Curanex Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Curanex Pharmaceuticals Inc. completed its IPO, raised $15.3 million, and is progressing its lead botanical drug candidate, Phyto-N, into clinical development for inflammatory diseases, despite reporting a $4.2 million net loss and internal control weaknesses.